

1 **Title**

2 High resolution linear epitope mapping of the receptor binding domain of SARS-CoV-2 spike protein
3 in COVID-19 mRNA vaccine recipients.

4 **Short title**

5 RBD epitopes in COVID-19 mRNA vaccine recipients

6 **Authors**

7 Yuko Nitahara¹, Yu Nakagama¹, Natsuko Kaku¹, Katherine Candray¹, Yu Michimuko¹, Evariste
8 Tshibangu-Kabamba¹, Akira Kaneko¹, Hiromasa Yamamoto², Yasumitsu Mizobata², Hiroshi Takeya
9 ³, Mayo Yasugi^{4,5,6}, Yasutoshi Kido^{1*}

10 ¹Department of Parasitology & Research Center for Infectious Disease Sciences, Graduate School of
11 Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

12 ²Department of Traumatology and Critical Care Medicine, Graduate School of Medicine, Osaka City
13 University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

14 ³Department of Infection Control Science, Graduate School of Medicine, Osaka City University, 1-4-
15 3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

16 ⁴Department of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka
17 Prefecture University, 1-58 Rinku-Ourai Kita, Izumisano, Osaka 598-8531, Japan

18 ⁵Osaka International Research Center for Infectious Diseases, Osaka Prefecture University, 1-58 Rinku
19 Ourai Kita, Izumisano, Osaka 598-8531, Japan

20 ⁶Asian Health Science Research Institute, Osaka Prefecture University, 1-58 Rinku Ourai Kita,
21 Izumisano, Osaka 598-8531, Japan

22 * Corresponding Author: Yasutoshi Kido, M.D., Ph.D.

23 Department of Parasitology, Graduate School of Medicine & Research Center for Infectious Disease
24 Sciences, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. Phone: +81-
25 6-6645-3761. Fax: +81-6-6645-3762. E-mail: kido.yasutoshi@med.osaka-cu.ac.jp

26 **Keywords**

27 SARS-CoV-2; spike; RBD; COVID-19; neutralizing antibodies; serology

28 **Abstract (172 words)**

29 The prompt rollout of the coronavirus disease (COVID-19) messenger RNA (mRNA) vaccine is
30 facilitating population immunity, which shall become more dominant than natural infection-induced
31 immunity. At the beginning of the vaccine era, understanding the epitope profiles of vaccine-elicited
32 antibodies will be the first step in assessing functionality of vaccine-induced immunity. In this study,
33 the high-resolution linear epitope profiles of Pfizer-BioNTech COVID-19 mRNA vaccine recipients
34 and COVID-19 patients were delineated by using microarrays mapped with overlapping peptides of
35 the receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
36 2) spike protein. The vaccine-induced antibodies targeting RBD had broader distribution across the
37 RBD than that induced by the natural infection. Thus, relatively lower neutralizability was observed
38 when a half-maximal neutralization titer measured *in vitro* by live virus neutralization assays was
39 normalized to a total anti-RBD IgG titer. However, mutation panel assays targeting the SARS-CoV-2
40 variants of concern have shown that the vaccine-induced epitope variety, rich in breadth, may grant
41 resistance against future viral evolutionary escapes, serving as an advantage of vaccine-induced
42 immunity.

43 **Importance (144 words)**

44 Establishing vaccine-based population immunity has been the key factor in attaining herd protection.

45 Thanks to expedited worldwide research efforts, the potency of messenger RNA vaccines against the
46 coronavirus disease 2019 (COVID-19) is now incontestable. The next debate is regarding the coverage
47 of SARS-CoV-2 variants. At the beginning of this vaccine era, it is of importance to describe the
48 similarities and differences between the immune responses of COVID-19 vaccine recipients and
49 naturally infected individuals. In this study, we demonstrated that the antibody profiles of vaccine
50 recipients are richer in variety, targeting a key protein of the invading virus, than those of naturally
51 infected individuals. Yet vaccine-elicited antibodies included more non-neutralizing antibodies than
52 infection-elicited, their breadth in antibody variations suggested possible resilience against future
53 SARS-CoV-2 variants. The antibody profile achieved by vaccinations in naive individuals pose
54 important insight into the first step towards vaccine-based population immunity.

55 **Introduction**

56 Messenger RNA (mRNA) vaccines have prevailed globally to mitigate the coronavirus disease
57 2019 (COVID-19) pandemic. Given the prompt progress in the development of vaccines and their fast
58 rollout at global scale, population immunity against the severe acute respiratory syndrome coronavirus
59 2 (SARS-CoV-2) will largely depend on vaccine-induced rather than the infection-induced immunity.
60 In this start of the COVID-19 vaccine era, the *de novo* repertoire of vaccine-elicited antibodies in
61 SARS-CoV-2 infection-naive individuals will be the first step to build an optimal host defense system
62 towards vaccine-based population immunity.

63 Currently, the efficacy of vaccine-induced immunity against SARS-CoV-2 in an individual is
64 evaluated by potential surrogate markers such as half-maximal neutralization titers (NT50) using
65 live/pseudo viruses and total antibodies titers against the receptor binding domain (RBD) of the spike
66 protein of the virus (1–4). Understanding the epitope profile of both vaccine recipients and naturally
67 infected individuals can readily help elucidating further molecular basis of these markers as surrogate.
68 Moreover, the coevolution of vaccine-induced host immunity and the virus escape will be one of the

69 most important elements to consider in the way of achieving herd immunity against COVID-19.

70 The RBD of the spike protein of SARS-CoV-2 is widely considered the key protein target for
71 designing vaccines and developing neutralizing antibodies as therapeutic agents (5,6). Epitope profiles
72 of sera from individuals naturally infected with COVID-19 have enabled to identify several
73 immunodominant regions in the spike protein (7–9). While most immunodominant epitopes locate
74 outside the RBD, the minor proportion targeting specifically the neutralizing RBD epitopes explain
75 the majority of viral neutralizability and protection against re-exposures (10,11). In fact, neutralizing
76 monoclonal antibodies (NAbs) developed as potential therapeutics also mainly target the epitopes
77 located in the RBD (6,12–16). While a growing number of individuals acquire vaccine immunity, the
78 detailed epitope profile of the humoral immune response to the mRNA vaccine is not fully understood
79 (1,17,18).

80 In this study, high resolution linear epitope profiling targeting the RBD was performed using
81 sera of both mRNA vaccine recipients and COVID-19 patients. By comparing the epitope profiles, we
82 sought to describe the similarities and differences between the humoral immune responses induced by
83 BNT162b2 mRNA (Pfizer/BioNTech) vaccination and natural infection. Information provided by this
84 study will be crucial in this post-vaccine era of the COVID-19 pandemic.

85 **Materials and Methods**

86 **Serum collection sufficient**

87 Two groups were analyzed in this study: (i) vaccine recipients, all received two doses of
88 BNT162b2 mRNA vaccine (Pfizer/BioNTech) with a three-week interval (N=21, age 20s–80s years
89 old). Blood was obtained 17–28 days after the second dose. (ii) COVID-19 patients confirmed by
90 nucleic amplification testing (N=20, age 20s–80s years old). The blood collection of the patients was
91 performed between 10 and 63 days (median 39 days) after the onset. Detailed information of the

92 subjects and severity of the disease of the patients can be found in Supplemental Table 1 (19).

93 Blood samples were obtained by venipuncture in serum separator tubes and the serum fraction
94 was stored at -80°C . All subjects provided written consent before participating in this study. This
95 study was approved by the institutional review board.

96 **Anti-RBD IgG quantification by chemiluminescent immunoassay**

97 Anti-RBD IgG titers of both groups were quantitated by measuring the chemiluminescence
98 generated in the reaction mix containing serum IgG-bound, RBD-coated microparticles and
99 acridinium-labeled anti-human IgG (Abbott SARS-CoV-2 IgG II Quant assay, USA)(20). Antibodies
100 targeting the viral nucleocapsid protein (Anti-N IgG) were also measured for the sera of vaccine
101 recipients to screen unrecognized exposure to SARS-CoV-2 (Abbott SARS-CoV-2 IgG assay, USA)
102 (21).

103 **Neutralization assay using live SARS-CoV-2**

104 The neutralization assay was carried out as described previously (22), but with modifications.
105 Heat-inactivated (at 56°C for 45 minutes) vaccine-recipients and patients' sera and a SARS-CoV-2
106 negative control serum were serially four-fold diluted with Dulbecco's Modified Eagle Medium with
107 2% fetal bovine serum (2% FBS DMEM) and incubated with a pre-titrated 150 focus-forming units
108 of SARS-CoV-2 JPN/TY/WK521 strain live virus particles (National Institute of Infectious Diseases,
109 Japan) at 37°C for 1 hour. The monolayer of VeroE6 cells (National Institutes of Biomedical
110 Innovation, Health and Nutrition, Japan) were then absorbed with the mixtures at 37°C . After a 1-hour
111 incubation, the mixtures were replaced with fresh 2% FBS DMEM. After an 8-hour culture at 37°C ,
112 infection rates of the cells were determined by immunofluorescent staining, as follows. After fixation
113 (4% paraformaldehyde, 15 minutes), cells were permeabilized (0.1% TritonX100, 15 minutes) and
114 incubated with rabbit anti-spike monoclonal antibodies (Sino biological, China) (1:1000, 1 hour at

115 37°C). Cells were then washed and incubated with Alexa488-conjugated goat anti-rabbit IgG
116 (ThermoFisher scientific, USA) (1:500, 45 minutes at 37°C). Antigen positive cells were counted under
117 a fluorescent microscope and the percentage of neutralization was estimated as the viral infectivity
118 under serum-treated conditions compared with that without serum.

119 **Epitope mapping of the RBD**

120 For precise linear epitope screening, overlapping 15-mer peptides (shift by 3 amino acids) were
121 sequentially synthesized according to the sequence of the RBD on cellulose membrane by MultiPep
122 synthesizer (Intavis Bioanalytical Instruments, Germany) using SPOT technology (23,24). The
123 sequence of the RBD was obtained by GenBank (accession: MN908947.3, S319–S541) Additional 15-
124 mer peptides containing single mutations of variants of concerns found within the RBD were designed.
125 Single mutations included K417N, K417T, E484K and N501Y (25). Detailed peptide sequences used
126 in this study can be found in Supplement Table 2.

127 Synthesized arrays were probed with sera at a 1:400 dilution followed by incubation with
128 horseradish peroxidase conjugated goat anti-human IgA, IgG, and IgM polyclonal antibody at a
129 1:30,000 dilution. The bound of the secondary antibody on each peptide was detected and quantified
130 by enhanced chemiluminescence. The peptide synthesis, probing and quantification were outsourced
131 to Kinexus Bioinformatics Corporation. The epitopes were detected by subjective visual inspection.
132 Our cutoff for signal detection was set at visually detectable peaks in a graph depicting a mostly
133 minimum of 0.5 z-score of the mean peptide signals and/or regions previously reported as neutralizing
134 antibodies in the RBD (27,28).

135 **Statistical analysis**

136 Chemiluminescence signal intensities of the peptide arrays were standardized in two ways:
137 relative values to the maximum signal level of each array as 100, and z-scores considering peptide

138 signals of individual subjects as population. These calculations were done by Microsoft Excel for
139 Microsoft 365 MSO (16.0.14026.20202).

140 Nonlinear regression curve fitting was performed to calculate half-maximal neutralization titers
141 (NT50) of the neutralization assay. Statistical significance was calculated using un-paired two-tailed
142 t-test. GraphPad Prism 9.1.0.221 was used for these statistical analyses.

143 The sequence and conformational information of the RBD was obtained under the accession
144 number 6M0J (5) and 7A94 (26) at Protein Data Bank (PDB). The images to depict the recognized
145 epitopes are shown using The PyMOL (Molecular Graphics System, Version 1.2r3pre, Schrödinger,
146 LLC).

147 **Results**

148 **Total IgG titers targeting the RBD and neutralization assay using live SARS-CoV-2**

149 All vaccine recipients (N=21) and COVID-19 patients (N=20) revealed seropositivity to anti-
150 RBD IgG according to the manufacturer's threshold (>50 AU/mL) and the two groups did not show
151 significant difference in their levels of anti-RBD IgG titers (Figure 1a). However, the neutralization
152 assay using live SARS-CoV-2 showed remarkably lower NT50 in vaccine recipients compared to
153 COVID-19 patients ($p=0.0035$) (Figure 1b). The ratio between the anti-RBD IgG antibody titer and
154 the NT50 value was calculated in individual as shown in Figure 1c. It appeared that the anti-RBD
155 IgG/NT50 ratios were significantly higher in vaccine recipients compared to COVID19 patients
156 ($p<0.001$) (Figure 3c). The result indicated that the sera of vaccine recipients were more abundant in
157 non-neutralizing, mere binding IgG antibodies, suggesting a discrepancy in the epitope profiles
158 between vaccine recipients and COVID-19 patients. None of the vaccine recipients were seropositive
159 to anti-N IgG, ensuring that they were naive to SARS-CoV-2 infection (Supplement Table 1).

160 **Comparison of linear epitope profiles targeting the RBD of vaccine-elicited and infection-elicited**

161 **sera**

162 To delineate the discrepancy in the epitope profiles between vaccine recipients and COVID-19
163 patients with high resolution, we next mapped and compared the immunodominant epitopes of both
164 sera by using an overlapping 15-mer linear-peptide array (Figure 2a). Sera of vaccine recipients and
165 COVID-19 patients were incubated with the microarray. Sera of five subjects from the vaccine
166 recipients and ten from the patients were selected based on their anti-RBD antibody titers and NT50
167 (denoted as red dots in Figure 1). The sera were incubated with the designed microarrays arranged
168 with 15-mer overlapping peptides of the RBD on the surface (Figure 2a). The designated array did not
169 show any considerable unspecific binding of the secondary antibody.

170 We generated a heatmap according to the relative signals of the overlapping peptides (Figure
171 2b). Also, z-scores of each peptide were compared individually (Supplement Figure 1) and per group
172 (Figure 3). Comparing the epitope profiles of the two groups, two types of epitopes were identified:
173 (1) epitopes recognized by both groups and (2) epitopes recognized only by vaccine-elicited sera.
174 Overall, seven linear epitopes were recognized within the RBD, four within (1): T415–F42, peptide
175 No.33; R457–S477, peptide No.47–49; V433–N450, peptide No.39–40; V395-A411, peptide No.26–
176 27 and three within (2): N334–A348, peptide No.6; S373–L390, peptide No.19,20; S514–F541,
177 peptide No.66–71, respectively (Figure 2b, Figure 3).

178 **(1) Epitopes recognized by both groups**

179 A total of four linear epitopes were recognized in both groups (Figure 2b, Figure 3c). Three
180 (peptide No.33, No.39–40 and No.47–49) of them shared the epitope regions of the RBD with
181 neutralizing monoclonal antibodies previously reported as class1 and class 3 (27).

182 Linear epitopes were identified at peptide No.33 and peptides No.47–49 (Figure 3, Figure 4a,b),
183 sharing the epitopes with reported class 1 neutralizing antibodies (27). Also, peptide No.39–40 (Figure

184 3, Figure 4c) shared epitope residues very similar to human monoclonal antibody REGN10987,
185 categorized as class 3 neutralizing antibody which sterically hinders the interaction between
186 angiotensin converting enzyme 2 (ACE2) and the RBD (27,29).

187 The linear epitope, peptide No.26–27, was reactive at the highest level in most serum samples,
188 as sera of 2/5 vaccine recipients and 7/10 patients had maximum reactivity to this peptide (Figure 3c,
189 Supplement Figure 1). However, antibodies binding to this epitope seemed not to contribute to
190 neutralizing the live virus, based on our observations detailed below. This peptide was found to be
191 equally reactive, at a high extent, to a serum with negligible neutralizability, obtained from a COVID-
192 19 patient who had undergone Rituximab treatment (Details found in Supplement Figure 2) (30). In
193 the RBD structure, the No.27 peptide is located inside the core β sheets, which is not exposed to the
194 surface of the RBD in either an “up” or “down” position. Judging from the structural composition, this
195 linear epitope would not affect ACE2 binding (Supplement Figure 2).

196 **(2) Epitopes recognized only in vaccine recipients’ sera**

197 Three linear epitopes of the RBD were uniquely found in vaccine recipients’ sera (Figure 2b,
198 Figure 3b,c), two of them (peptide No.6 and No.19,20) were sharing the epitope regions of the RBD
199 with neutralizing monoclonal antibodies known as class 3 and class 4 (27).

200 At N-terminus of the RBD, namely the peptide No.1–6, we identified an epitope region detected
201 only in the post-vaccination sera (Figure 2b, Figure 3c). Especially, peptide No. 6 was an epitope of
202 note, which shall be recognized by the class3 NAb S309 by P337–A344 helix residues (Figure 5a)
203 (31). The epitope is distinct from the receptor-binding motif and has a good accessibility both in the
204 up and down compositions of the RBD (PDB, 7A49, Figure 5b).

205 Another identified epitope, peptide No.19 and 20, shared epitope residues with a neutralizing
206 monoclonal antibody CR3022, categorized as class 4, isolated from a SARS-CoV convalescent (32,33).

207 This class 4 neutralizing antibody attaches to the RBD but distal to the ACE2 binding site and is highly
208 conserved among different CoV species (34).

209 The third epitope, located at the peptide No.66–71, did not match with any known monoclonal
210 antibodies. Yi et al. detected the same region of the peptides (V524–F541) reactive from COVID-19
211 convalescent serum in their linear epitope analysis (11). They also demonstrated that these peptides
212 interacted with control sera as well (11). Thus, we considered our results on the corresponding peptides
213 to be non-specific.

214 **Linear epitopes mapping with single mutations found in SARS-CoV-2 variants**

215 Our analysis included single amino acid mutations of the RBD that are reported in the SARS-
216 CoV-2 variants of concerns including B.1.1.7, B.1.351 and P.1 (PANGO lineage (35)). Additional 15-
217 mer peptides with the substituting amino acid, K417N, K417T, E484K, and N501Y, were incubated
218 with both vaccine recipients' and patients' sera. Interestingly, vaccine-induced sera showed consistent
219 signals to the mutated peptides, whereas patients' sera had almost no reaction (Figure 6).

220 In our original peptide array (Figure 2b, Figure 3), the overlapping peptides encoding the
221 mentioned mutations sites (K417, E484, and N501 of the RBD) corresponded to peptides No.29–33,
222 No.52–56, and No.57–61, respectively. The peptides No.52–61, containing E484 and N501, did not
223 show any significant reaction in both vaccine recipients and COVID-19 patients (Figure 2b, Figure 3).
224 The peptides No.29–33 containing K417, considered as escape mutation, was reactive to antibodies in
225 both patients and vaccine recipients' sera as mentioned above (Figure 2b, Figure 3).

226 **Discussion**

227 This study revealed the linear epitope profiles targeting RBD elicited by BNT162b2 mRNA
228 vaccination and natural infection of SARS-CoV-2. Our principal finding was that the variation of linear
229 epitopes was broader in vaccine-elicited antibodies compared with infection-elicited antibodies, which

230 may contribute to potent neutralization and thus resistance of the vaccine-elicited antibodies against
231 the SARS-CoV-2 variants of concern.

232 Now, four categories of NAbs classes are proposed to characterize the mode of recognition and
233 epitope specificity (27). Class 1 NAbs block several proximal sites in the receptor binding motif
234 (RBM) of the RBD and directly block ACE2 binding (27); class 2 NAbs recognize both up and down
235 formations of the RBDs and epitope overlapping or close to ACE2-binding site (27); class 3 NAbs
236 recognize both up and down RBD and bind outside ACE2-binding site (27,31); class 4 NAbs bind only
237 to up RBDs and do not directly block ACE2 binding, but destabilizes the virus' prefusion spike
238 conformation (33,34). Many of the human-isolated NAbs target RBD, while some target N-terminal
239 domain of subunit 1 spike protein (14,36). In our study, two classes of NAbs exclusively relevant in
240 vaccine-elicited sera were found to be of specific note; peptide No.6 (Figure 5a,b) targeted by the class
241 3 NAb (31) and peptide No.19–20 (Figure 5c) targeted by the class 4 NAb (33,34). These epitopes
242 locate outside the ACE2-binding RBM (Figure 5), while epitopes commonly detected in both vaccine
243 and infection-elicited repertoires clustered adjacent to the ACE2-binding site (Figure 4).

244 The majority of NAbs targeting the RBM, which correspond to class 1 and 2, have been shown
245 to exhibit decreased neutralization against the virus variants (15,18,37). For example, antibodies
246 recognizing the linear epitope, here included in peptide No.33, would possibly fail in neutralizing
247 variants with K417N mutation as previously described (15,18,37,38). To the contrary, the linear
248 peptides No.6 and No.19–20 (Figure 5a,b,c), corresponding to epitopes found exclusively in vaccine-
249 elicited sera (Figure 2b, Figure 3c), revealed corresponding epitopes targeted by human NAbs isolated
250 from SAR-CoV convalescent (S309 and CR3022, respectively) (31,33,34). These cross-neutralizing
251 antibodies, belonging to class 3 and 4, recognize linear epitopes highly conserved among different
252 CoV species. The epitopes recognized by these class 3 and class 4 NAbs are major contributors
253 broadening the repertoire of vaccine-induced immunity. Located remotely from the RBM, such

254 neutralizing epitopes stay rather free from variants (15,18), and explain the resistance of vaccine-
255 elicited sera towards viral mutational escapes (39,40). The vaccine recipients' broader epitope profile
256 spanning across the RBD may give immunological flexibility and resilience against this evolving virus.
257 Our mutation peptide panels have also presented a rather optimistic view on discussing the efficacy of
258 vaccine-induced immunity to efficiently recognize the SARS-CoV-2 variants (Figure 6). However,
259 considering that the linear epitope profiles harboring the mutation loci were not dominant in either
260 vaccine sera or patients' sera (Figure 2b, Figure 3b,c) and abundance of conformational epitopes found
261 adjacent to the RBM, the extent to which these specific linear epitopes contribute in net neutralizability
262 remains yet to be determined (10,11,14,17).

263 We observed discrepancy between the neutralizability of sera obtained from vaccine recipients
264 and patients, which could be partially explained by the difference in the time course of epitope
265 selection and immune maturation. When comparing convalescent sera and vaccine-elicited immunity,
266 the distribution of neutralizing epitopes was less generalized and focalized at specific peptides (Figure
267 3, Individual epitope distribution can be found in Supplement Figure 1). Among the two modes of
268 acquired immunity, our results indicate that infection-induced humoral immunity had established a
269 more mature, finely selected antibody repertoire. Our snapshot observations are in line with the ideas
270 that maturation of infection-provoked repertoires occurs as early as 10–20 days after onset, or even
271 earlier in the case of COVID-19 beginning at 4–7 days after onset (41,42). Positive selection of relevant
272 epitopes and maturation of antibody repertoire thus may lag behind regarding the vaccine-induced
273 immunity. Nevertheless, in this study, sera were sampled during the peak period of immune reaction
274 in the host for both groups. Longitudinal evaluation of the epitope profiles and serological markers are
275 needed to assess the further host immune evolution and draw conclusions to the above speculations.

276 In conclusion, we evaluated the similarity and difference in humoral immunity elicited by both
277 BNT162b2 mRNA vaccine and natural infection of SARS-CoV-2. High resolution linear epitope

278 profiles revealed the characteristic distribution of polyclonal antibodies spanning across the RBD in
279 vaccine recipients' sera, which possibly accounted for the discrepancy observed in serological markers.
280 Based on the multiplicity of neutralizing epitopes supporting the protectivity of vaccine-elicited
281 antibodies, mRNA vaccine-elicited humoral immunity may harbor advantages in resisting against the
282 rapidly evolving pathogen.

283 **Limitations**

284 There are several limitations in our study. The severity of the COVID-19 patients evaluated in
285 this study was high (seven out of ten were critical) with comorbidities, whereas the vaccine recipients
286 were relatively healthy without major comorbidities. The age was distributed in both groups. This
287 analysis was focused exclusively on the linear epitope profile targeting RBD. Experimental
288 observations on compositional epitopes nor epitopes outside the RBD region was not made in this
289 study. Nonetheless, our results reporting the mRNA vaccine's broader RBD epitope variety are in
290 concordance with preceding reports (39,43).

291 **Author Approval**

292 All authors have read and approved the manuscript.

293 **Competing Interest Statement**

294 The authors declare no competing interests to disclose.

295 **Data Availability Statement**

296 The data that supports the findings of this study are available in the supplementary material of this
297 article.

298 **Acknowledgements**

299 This work was funded by Japan Agency for Medical Research and Development (AMED) under Grant

300 number JP20wm0125003 (Yasutoshi Kido), JP20he1122001 (Yasutoshi Kido), JP20nk0101627
301 (Yasutoshi Kido), and JP20jk0110021 (Yu Nakagama). This work was also supported by JSPS
302 KAKENHI Grant Number JP21441824 (Natsuko Kaku). We received support from Osaka City
303 University's "Special Reserves" fund for COVID-19. We also receive the COVID-19 Private Fund (to
304 the Shinya Yamanaka laboratory, CiRA, Kyoto University). Yuko Nitahara receives BIKEN
305 Taniguchi Scholarship.

306 We are grateful for the virus provided by National Institute of Infectious Diseases, Tokyo, Japan.

307 We appreciate James A. Rankin for his contribution in checking the manuscript.

308 **Author contribution**

309 Nitahara Y, Nakagama Y, Kaku N and Kido Y designed the study.

310 Nitahara Y, Nakagama Y, Kaku N, Yamamoto H, Mizobata Y, Takeya H, and Kido Y selected patients
311 and acquired clinical data.

312 Nitahara Y, Nakagama Y, Kaku N, Candray K, Michimuko Y, Tshibangu-Kabamba E and Yasugi M
313 performed immunological assays.

314 Nitahara Y, Nakagama Y, Kaku N and Kido Y performed epitope mapping analysis.

315 Nakagama Y and Yasugi M performed neutralization assays.

316 Nitahara Y, Nakagama Y, Kaku N and Kido Y wrote the manuscript and contributed to analysis and
317 interpretation of the data.

318 Yamamoto H, Mizobata Y, Takeya H, Kaneko A and Yasugi M contributed to critical discussion of
319 the manuscript.

320

321 **Figure 1. Total antibody titers targeting the RBD and neutralization of live SARS-CoV-2.**

322 (a) Anti-RBD IgG titers of vaccine (BNT162b2) recipients (N=21) and COVID-19 patients (N=19)
323 were depicted. No significant difference in level of total anti-RBD IgG titers was observed. (b) The
324 half-maximal neutralization titers (NT50) were remarkably lower in the vaccinated group than in
325 patients. (c) Anti-RBD IgG/NT50 ratio was plotted in both groups. Black horizontal bars indicate
326 geometric mean with geometric standard deviation. For detailed information on subjects, see
327 Supplement Table1.

328 **Figure 2. High resolution linear epitope mapping of the receptor binding domain (RBD) of the**

329 **SARS-CoV-2 spike protein.** (a) Overlapping 15-mer peptides (shift by 3 amino acids) of the RBD
330 was sequentially synthesized on cellulose membrane. Sera of vaccine recipients and COVID-19
331 patients were incubated with the microarray, followed by the procedure mentioned in the methodology
332 section to detect the reactive peptides.

333 (b) Heat map identifying peptides recognized by IgG, IgA, and IgM in sera of vaccine recipients
334 (Sample A–E) and COVID-19 patients (sample F–O). Signal of each peptide was calculated to relative
335 value to the maximum signal of each subject as 100. Legend shows the darker the blue gets; the more
336 signal was observed at the designated peptide.

337 **Figure 3. Comparison of epitope profiles between two groups: BNT162b2 vaccine recipients**

338 **(N=5) and COVID-19 patients (N=10).** (a) Thin red lines denote peptide signals of individuals. Bold
339 red lines depict the mean values of the peptide signals of the COVID-19 patients' sera (N=10). (b)
340 Thin grey lines denote peptide signals of individuals. Bold black lines denote the mean values of the
341 peptide signals of the vaccine recipients' sera (N=5). (c) Red arrows denote epitopes recognized in
342 the sera of both groups. Black arrows denote epitopes identified only in the vaccine recipients' sera.
343 Designated peptide numbers are shown above the arrows.

344 **Figure 4. Linear epitopes in the receptor binding domain (RBD) identified in both groups of**
345 **vaccine recipients and COVID-19 patients.** Angiotensin converting enzyme2 (ACE2); green, the
346 RBD; tint blue, (a) linear epitope T415-F429 (peptide No.33); cyan (b) linear epitope R457-S477
347 (peptide No.47-49); yellow (c) linear epitope A433-S450 (peptide No.39-40); blue.

348 **Figure 5. Linear epitopes in the receptor binding domain (RBD) identified only in vaccine**
349 **recipients' sera.** Angiotensin converting enzyme2 (ACE2) is shown in green. (a) The RBD is shown
350 in tint blue. Linear epitope R334-S348 (peptide No.6); magenta. (b) SARS-CoV-2 spike trimer in one
351 open, two closed (one RBD up, two RBD up) composition. Spike subunit 2 and N-terminal domain
352 are in the same color, light blue, yellow, and tint blue. Up RBD is in dark blue, Down RBDs are in
353 yellow. Linear epitope R334-S348 has good accessibility in both up and down composition of the RBD.
354 (c) The RBD; green. Linear epitope S373-L390 (peptide No.19-20); orange.

355 **Figure 6. Mutation peptide panels showed more reactivity to vaccine recipients' sera than to**
356 **patients' sera.** Heat maps identifying peptides encoding the single mutations, recognized by IgG, IgA,
357 and IgM in sera of vaccine recipients (Sample A–E) and COVID-19 patients (sample F–O). Signal of
358 each peptide was calculated to relative value to the maximum signal of each subject as 100.

359 **Supplement Figure 1.** Epitope profiles of individual subjects are shown in graphs depicting z-scores
360 of each peptide signal, calculated individually, on y-axis, overlapping peptide sequence on x-axis.
361 Vaccine-induced sera (V01–V05) had more variety in recognizing epitopes than infection-induced sera
362 (P01–P10).

363 **Supplement Figure 2.** Epitope profile of a COVID-19 patient who had received Rituximab treatment.
364 The antibodies targeting the peptide No. 27, corresponding to A397–A411 of RBD, were dominant in
365 the epitope profile of this patient (depicted in the upper right graph), which showed limited
366 neutralization compared to a COVID-19 positive serum sample from another COVID-19 patient.
367 Graphic on the left shows the ACE2-RBD complex (ACE2 in green, RBD in tint blue). The position

368 of peptide No.27 is depicted in dark gray.

369 **Supplement Table 1.** Detailed information of the subjects included in this study.

370 **Supplement Table 2.** Sequence of the peptides on microarrays used in this study.

371 **Supplement Table 3.** Raw signal of the microarrays.

372 **References**

- 373 1. Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, et al. Antibody responses to the
374 BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nat Med*
375 [Internet]. 2021 Apr 1 [cited 2021 Jun 15];1–4. Available from: [https://doi.org/10.1038/s41591-](https://doi.org/10.1038/s41591-021-01325-6)
376 021-01325-6
- 377 2. Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and
378 Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *N Engl J Med* [Internet].
379 2020 Dec 17 [cited 2021 Jun 25];383(25):2439–50. Available from:
380 <http://www.nejm.org/doi/10.1056/NEJMoa2027906>
- 381 3. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of
382 COVID-19 RNA vaccine BNT162b1 in adults. *Nature* [Internet]. 2020 Oct 22 [cited 2021 Jun
383 25];586(7830):589–93. Available from: <https://doi.org/10.1038/s41586-020-2639-4>
- 384 4. Müller L, Andrée M, Moskorz W, Drexler I, Walotka L, Grothmann R, et al. Age-dependent
385 immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. *medRxiv*
386 [Internet]. 2021 Jan 1;2021.03.03.21251066. Available from:
387 <http://medrxiv.org/content/early/2021/03/05/2021.03.03.21251066.abstract>
- 388 5. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-
389 binding domain bound to the ACE2 receptor. *Nature* [Internet]. 2020;581(7807):215–20.

390 Available from: <http://dx.doi.org/10.1038/s41586-020-2180-5>

391 6. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition
392 by SARS-CoV-2. *Nature* [Internet]. 2020 May 14 [cited 2021 Jun 14];581(7807):221–4.

393 Available from: <https://doi.org/10.1038/s41586-020-2179-y>

394 7. Li Y, Ma M liang, Lei Q, Wang F, Hong W, Lai D yun, et al. Linear epitope landscape of the
395 SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. *Cell Rep*. 2021 Mar
396 30;34(13):108915.

397 8. Haynes WA, Kamath K, Bozekowski J, Baum-Jones E, Casanovas-Massana A, Daugherty PS,
398 et al. High-resolution mapping and characterization of epitopes in COVID-19 patients. [cited
399 2021 Jun 10]; Available from: <https://doi.org/10.1101/2020.11.23.20235002>

400 9. Voss WN, Hou YJ, Johnson N V., Delidakis G, Kim JE, Javanmardi K, et al. Prevalent,
401 protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. *Science*
402 (80-) [Internet]. 2021 Jun 4 [cited 2021 Jun 11];372(6546):1108–12. Available from:
403 <http://science.sciencemag.org/>

404 10. Li Y, Lai D yun, Zhang H nan, Jiang H wei, Tian X, Ma M liang, et al. Linear epitopes of SARS-
405 CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients [Internet]. Vol. 17,
406 *Cellular and Molecular Immunology*. Springer Nature; 2020 [cited 2021 Jun 11]. p. 1095–7.
407 Available from: <https://doi.org/10.1038/s41423-020-00523-5>

408 11. Yi Z, Ling Y, Zhang X, Chen J, Hu K, Wang Y, et al. Functional mapping of B-cell linear
409 epitopes of SARS-CoV-2 in COVID-19 convalescent population. *Emerg Microbes Infect*
410 [Internet]. 2020 Jan 1 [cited 2021 Jun 14];9(1):1988–96. Available from:
411 <https://doi.org/10.1080/22221751.2020.1815591>

412 12. Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, et al. Key residues of the receptor binding motif in

- 413 the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. *Cell Mol*
414 *Immunol* [Internet]. 2020 Jun 1 [cited 2021 Jun 4];17(6):621–30. Available from:
415 <https://doi.org/10.1038/s41423-020-0458-z>
- 416 13. Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al. Mapping
417 Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain
418 by Structure-Guided High-Resolution Serology. *Cell*. 2020 Nov 12;183(4):1024-1042.e21.
- 419 14. Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, Rapp M, et al. Potent SARS-CoV-2 neutralizing
420 antibodies directed against spike N-terminal domain target a single supersite. *Cell Host Microbe*.
421 2021 May 12;29(5):819-833.e7.
- 422 15. Wang R, Zhang Q, Ge J, Ren W, Zhang R, Lan J, et al. Analysis of SARS-CoV-2 variant
423 mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from
424 additional species. *Immunity* [Internet]. 2021 Jun 8 [cited 2021 Jun 25]; Available from:
425 <https://linkinghub.elsevier.com/retrieve/pii/S1074761321002478>
- 426 16. Li Y, Lai D-Y, Zhang H-N, Jiang H-W, Tian X, Ma M-L, et al. Linear epitopes of SARS-CoV-
427 2 spike protein elicit neutralizing antibodies in COVID-19 patients. *Cell Mol Immunol*
428 [Internet]. 2020 [cited 2021 Jun 14];17:1095–7. Available from:
429 <https://doi.org/10.1038/s41423-020-00523-5>
- 430 17. Wisnewski A V, Redlich CA, Kamath K, Abad Q-A, Smith RF, Fazen L, et al. Immunogenic
431 Amino Acid Motifs and Linear Epitopes of COVID-19 mRNA Vaccines. *medRxiv* [Internet].
432 2021 May 25 [cited 2021 Jun 10];2021.05.25.21257427. Available from:
433 <https://doi.org/10.1101/2021.05.25.21257427>
- 434 18. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-
435 elicited antibodies to SARS-CoV-2 and circulating variants. *Nature* [Internet]. 2021 Apr 22

- 436 [cited 2021 Jun 15];592(7855):616–22. Available from: <https://doi.org/10.1038/s41586-021->
437 03324-6
- 438 19. Diaz, Janet; Appiah, John; Askie, Lisa; Baller, April; Banerjee, Anshu; Barkley, Shannon;
439 Bertagnolio, Silvia; Hemmingsen, Bianca; Bonet, Mercedes; Cunningham J. Clinical
440 management Clinical management Living guidance COVID-19. World Heal Organ.
441 2021;(January).
- 442 20. Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, et al. Association
443 between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. *Clin*
444 *Chem* [Internet]. 2020 Dec 1 [cited 2021 Jun 30];66(12):1538–47. Available from:
445 <https://academic.oup.com/clinchem/article/66/12/1538/5902446>
- 446 21. Chew KL, Tan SS, Saw S, Pajarillaga A, Zaine S, Khoo C, et al. Clinical evaluation of
447 serological IgG antibody response on the Abbott Architect for established SARS-CoV-2
448 infection. *Clin Microbiol Infect*. 2020 Sep 1;26(9):1256.e9-1256.e11.
- 449 22. Yasugi M, Kubota-Koketsu R, Yamashita A, Kawashita N, Du A, Sasaki T, et al. Human
450 Monoclonal Antibodies Broadly Neutralizing against Influenza B Virus. *PLoS Pathog* [Internet].
451 2013 Feb 7 [cited 2021 Jun 20];9(2):1003150. Available from:
452 http://www.jst.go.jp/global/kadai/h2011_thailand.html
- 453 23. Ruppel E, Aÿ B, Boisguerin P, Dölle S, Worm M, Volkmer R. Identification of IgE Binding to
454 Apig1-Derived Peptides. *ChemBioChem* [Internet]. 2010 Nov 2 [cited 2021 Jun
455 11];11(16):2283–93. Available from: <http://dx.doi.org/10.1002/cbic.201000322>.
- 456 24. Volkmer R. Synthesis and application of peptide arrays: Quo vadis SPOT technology [Internet].
457 Vol. 10, *ChemBioChem*. John Wiley & Sons, Ltd; 2009 [cited 2021 Jun 11]. p. 1431–42.
458 Available from: <http://www.jpt.com>




- 459 25. Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and
460 Definitions [Internet]. [cited 2021 Jun 30]. Available from:
461 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#Concern>
- 462 26. Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, et al. Receptor binding
463 and priming of the spike protein of SARS-CoV-2 for membrane fusion. *Nature* [Internet]. 2020
464 Dec 10 [cited 2021 Jun 24];588(7837):327–30. Available from: [https://doi.org/10.1038/s41586-](https://doi.org/10.1038/s41586-020-2772-0)
465 [020-2772-0](https://doi.org/10.1038/s41586-020-2772-0)
- 466 27. Barnes CO, Jette CA, Abernathy ME, Dam KMA, Esswein SR, Gristick HB, et al. SARS-CoV-
467 2 neutralizing antibody structures inform therapeutic strategies. *Nature* [Internet]. 2020 Dec 24
468 [cited 2021 Jun 25];588(7839):682–7. Available from: [https://doi.org/10.1038/s41586-020-](https://doi.org/10.1038/s41586-020-2852-1)
469 [2852-1](https://doi.org/10.1038/s41586-020-2852-1)
- 470 28. Yu F, Xiang R, Deng X, Wang L, Yu Z, Tian S, et al. Receptor-binding domain-specific human
471 neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2 [Internet]. Vol. 5,
472 *Signal Transduction and Targeted Therapy*. Springer Nature; 2020 [cited 2021 Jul 2]. p. 1–12.
473 Available from: <https://doi.org/10.1038/s41392-020-00318-0>
- 474 29. Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in humanized mice
475 and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science* (80-) [Internet].
476 2020 Aug 21 [cited 2021 Jul 17];369(6506):1010–4. Available from:
477 <https://science.sciencemag.org/content/369/6506/1010>
- 478 30. Takakuwa T, Nakagama Y, Yasugi M, Maeda T, Matsuo K, Kiritoshi A, et al. Discrepant
479 antigen-specific antibody responses causing SARS-CoV-2 persistence in a B-cell depleted
480 patient on rituximab. *Intern Med*.
- 481 31. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization



- 482 of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* [Internet]. 2020 Jul 9
483 [cited 2021 Jul 2];583(7815):290–5. Available from: <https://doi.org/10.1038/s41586-020-2349->
484 [y](https://doi.org/10.1038/s41586-020-2349-y)
- 485 32. Ter Meulen J, Van Den Brink EN, Poon LLM, Marissen WE, Leung CSW, Cox F, et al. Human
486 monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape
487 mutants. *PLoS Med* [Internet]. 2006 Jul 4 [cited 2021 Jul 1];3(7):1071–9. Available from:
488 www.plosmedicine.org
- 489 33. Huo J, Zhao Y, Ren J, Zhou D, Duyvesteyn HME, Ginn HM, et al. Neutralization of SARS-
490 CoV-2 by Destruction of the Prefusion Spike. *Cell Host Microbe*. 2020 Sep 9;28(3):445-454.e6.
- 491 34. Yuan M, Wu NC, Zhu X, Lee CCD, So RTY, Lv H, et al. A highly conserved cryptic epitope
492 in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science* (80-) [Internet].
493 2020 May 8 [cited 2021 Jun 26];368(6491):630–3. Available from:
494 <http://science.sciencemag.org/>
- 495 35. O’Toole Á, Kraemer MUG, Hill V, Pybus OG, Watts A, Bogoch II, et al. Tracking the
496 international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2. *Wellcome Open*
497 *Res* [Internet]. 2021 May 19 [cited 2021 Jun 30];6:121. Available from:
498 <https://doi.org/10.12688/wellcomeopenres.16661.1>
- 499 36. Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, et al. Neutralizing
500 and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-
501 CoV-2 spike protein. *bioRxiv* [Internet]. 2021 Jan 1;2021.01.19.427324. Available from:
502 <http://biorxiv.org/content/early/2021/01/20/2021.01.19.427324.abstract>
- 503 37. Wang R, Zhang Q, Ge J, Ren W, Zhang R, Lan J, et al. SARS-CoV-2 variants resist antibody
504 neutralization and broaden host ACE2 usage. *bioRxiv* [Internet]. 2021 Jan 1;2021.03.09.434497.

- 505 Available from: <http://biorxiv.org/content/early/2021/03/15/2021.03.09.434497.abstract>
- 506 38. Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-
507 CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. *Nat*
508 *Med* [Internet]. 2021 Apr 1 [cited 2021 Jun 28];27(4):717–26. Available from:
509 <https://doi.org/10.1038/s41591-021-01294-w>
- 510 39. Greaney AJ, Loes AN, Gentles LE, Crawford KHD, Starr TN, Malone KD, et al. Antibodies
511 elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do
512 those from SARS-CoV-2 infection. *Sci Transl Med* [Internet]. 2021 Jun 8 [cited 2021 Jun 24];
513 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34103407>
- 514 40. Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA, Lundberg R, et al.
515 COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
516 *Nat Commun* [Internet]. 2021 Dec 28 [cited 2021 Jul 1];12(1):3991. Available from:
517 <http://www.nature.com/articles/s41467-021-24285-4>
- 518 41. Niu X, Li S, Li P, Pan W, Wang Q, Feng Y, et al. Longitudinal Analysis of T and B Cell
519 Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients.
520 *Front Immunol* [Internet]. 2020 Sep 30 [cited 2021 Jul 2];11:2590. Available from:
521 www.frontiersin.org
- 522 42. Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, et al. Longitudinal
523 Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19
524 Patients. *Cell*. 2020 Aug 20;182(4):843-854.e12.
- 525 43. Amanat F, Thapa M, Lei T, Ahmed SMS, Adelsberg DC, Carreño JM, et al. SARS-CoV-2
526 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. *Cell*
527 [Internet]. 2021 Jun [cited 2021 Jul 17];0(0):1–13. Available from:

528 <http://www.cell.com/article/S0092867421007066/fulltext>

529

a**b****c**



Peptide No.

1

2


3

⋮




⋮

⋮


-Vaccine-elicited sera
 -Infection-elicited sera




Peptide array

a**b****c**


a




b



c




a




180°






















Peptide No.6
R334-S348


b

c



K417N**K417T****E484K****N501Y**





Peptide No.27
A397-A411

